Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3

被引：0
|
作者：
van de Kerkhof, P. [1 ]
Guenther, L. [2 ]
Gottlieb, A. [3 ]
Sebastian, M. [4 ]
Wu, J. [5 ]
Foley, P. [6 ]
Morita, A. [7 ]
Goldblum, O. [8 ]
Zhang, L. [9 ]
Erickson, J. [9 ]
Ball, S. [9 ]
Rich, P. [10 ]
机构：
[1] Radboud Univ Nijmegan, Med Ctr, Nijmegen, Netherlands
[2] Guenther Dermatol Res Ctr, London, ON, Canada
[3] Tufts Med Ctr, Boston, MA USA
[4] Hautarztpraxis Mahlow, Blankenfelde Mahlow, Germany
[5] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[6] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[7] Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Oregon Hlth & Sci Univ, Ctr Hlth & Healing, Portland, OR 97201 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
fingernail psoriasis; ixekizumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P138
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [41] Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
    Leonardi, Craig
    Maari, Catherine
    Philipp, Sandra
    Goldblum, Orin
    Zhang, Lu
    Burkhardt, Nicole
    Ball, Susan
    Mallbris, Lotus
    Gonzalez, Pablo
    Fernandez-Penas, Pablo
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (05) : 824 - +
  • [42] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [43] Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis
    Au, Shiu-Chung
    Goldminz, Ari M.
    Kim, Noori
    Dumont, Nicole
    Michelon, Melissa
    Volf, Eva
    Hession, Meghan
    Lizzul, Paul F.
    Andrews, Israel D.
    Kerensky, Todd
    Wang, Andrew
    Yaniv, Shimrat
    Gottlieb, Alice B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (03) : 179 - 187
  • [44] Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension
    van de Kerkhof, P. C. M.
    Segaert, S.
    Lahfa, M.
    Luger, T. A.
    Karolyi, Z.
    Kaszuba, A.
    Leigheb, G.
    Camacho, F. M.
    Forsea, D.
    Zang, C.
    Boussuge, M. P.
    Paolozzi, L.
    Wajdula, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) : 1177 - 1185
  • [45] Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a Phase 3 trial
    Warren, R. B.
    Morita, A.
    Menter, A.
    Duffin, K. Callis
    Langley, R.
    Amato, D.
    Dennehy, E. B.
    Kerr, L. N.
    Shrom, D.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 79
  • [46] Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study
    De Simone, C.
    Maiorino, A.
    Tassone, F.
    D'Agostino, M.
    Caldarola, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (08) : 1003 - 1006
  • [47] Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: Results from UNCOVER-2
    van de Kerkhof, Peter
    Guenther, Lyn
    Gottlieb, Alice
    Sebastian, Michael
    Wu, Jashin J.
    Foley, Peter
    Morita, Akimichi
    Goldblum, Orin
    Kerr, Lisa
    Rich, Phoebe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [48] Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1,-2 trials through 5 years
    Gottlieb, A. B.
    Merola, J.
    Somani, N.
    Konicek, B.
    See, K.
    McKean-Matthews, M.
    Gallo, G.
    Rich, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S50 - S50
  • [49] Ixekizumab is superior to placebo for the treatment of nail, scalp, and palmoplantar psoriasis in pediatric patients with moderate to severe plaque psoriasis
    Paller, Amy S.
    Magarinos, Gabriel Alejandro
    Pinter, Andreas
    Cather, Jennifer
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB20 - AB20
  • [50] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
    Strober, Bruce
    Tada, Yayoi
    Mrowietz, Ulrich
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Warren, Richard B.
    Wang, Maggie
    Vanvoorden, Veerle
    Szilagyi, Balint
    Ciaravino, Valerie
    Paul, Carle
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
12345